1
|
Zhang H, Zhang H, Fang H. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China. Hum Vaccin Immunother 2024; 20:2313872. [PMID: 38348600 PMCID: PMC10865926 DOI: 10.1080/21645515.2024.2313872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 01/31/2024] [Indexed: 02/15/2024] Open
Abstract
Meningococcal vaccination strategies in China are intricate, including multiple vaccines targeting different serogroups. The current National Immunization Program (NIP) includes two polysaccharide vaccines for serogroups A and C (MPV-A and MPV-AC), covering limited serogroups and requiring adaptation. This study aims to evaluate the cost-effectiveness of replacing the current strategy with alternative strategies utilizing non-NIP vaccines to inform policy decisions. From a societal perspective, a decision tree-Markov model was constructed to simulate the economic and health consequences of meningococcal disease in a 2019 birth cohort with four vaccination strategies. Epidemiology, vaccine efficacy, cost, and other parameters were derived from previous studies. We conducted sensitivity analyses to assess the robustness of the findings and explored prices for non-NIP vaccines that enable cost-effective strategies. Compared to the current strategy, alternative strategies using quadrivalent polysaccharide vaccine (MPV-4), bivalent conjugate vaccine (MCV-AC), and quadrivalent conjugate vaccine (MCV-4) could avoid 91, 286, and 455 more meningococcal cases. The ICERs were estimated at approximately $250 thousand/QALY, $450 thousand/QALY, and $1.5 million/QALY, all exceeding the threshold of three times GDP per capita. The alternative strategies were not cost-effective. However, if vaccine prices were reduced to $3.9 for MPV-4, $9.9 for MCV-AC, and $12 for MCV-4, the corresponding strategy would be cost-effective. The current meningococcal vaccination strategy in China could effectively prevent the disease at a low cost, but with limited serogroup coverage. Strategies using MPV-4, MCV-AC, or MCV-4 could increase health benefits at a substantial cost, and might become cost-effective if vaccine prices decrease.
Collapse
Affiliation(s)
- Haonan Zhang
- School of Public Health, Peking University, Beijing, China
- China Center for Health Development Studies, Peking University, Beijing, China
| | - Haijun Zhang
- School of Public Health, Peking University, Beijing, China
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Hai Fang
- China Center for Health Development Studies, Peking University, Beijing, China
- Peking University Health Science Center-Chinese Center for Disease Control and Prevention Joint Center for Vaccine Economics, Peking University, Beijing, China
- Institute for Global Health and Development, Peking University, Beijing, China
| |
Collapse
|
2
|
Shen J, Ji C, Luo X, Hu Y. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China. PLoS One 2024; 19:e0310274. [PMID: 39250492 PMCID: PMC11383224 DOI: 10.1371/journal.pone.0310274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Accepted: 08/28/2024] [Indexed: 09/11/2024] Open
Abstract
Meningococcal vaccination in Chinese national immunization program (NIP) includes polysaccharide vaccine against Neisseria meningitidis serogroup A (MPV-A) and polysaccharide vaccine against Neisseria meningitidis serogroup A and C(MPV-AC). This study aimed to assess the cost-effectiveness of an alternative strategy using polysaccharide conjugate vaccine against Neisseria meningitidis serogroup A,C,W,Y(MCV-ACWY) and polysaccharide vaccine against Neisseria meningitidis serogroup A,C,W,Y(MPV-ACWY). From a societal perspective, we constructed a decision tree-Markov model to simulate the economic and health consequences of meningococcal disease in a 2023 birth cohort with the current meningococcal vaccination strategy and the alternative. Parameters of epidemiology, vaccine efficacy, cost, and utility were extracted from database and previous literatures. The sensitivity analysis was implemented to evaluate the robustness of the model. Compared to the current practice, the alternative strategy could avoid 513 meningococcal disease cases, 53 sequelae and 47 deaths. The ICER was estimated at $16899.81 /QALY, under the threshold of one time of the GDP per capita of Zhejiang province in 2023. The incidence of meningococcemia, the incidence of meningococcal meningitis, the case fatality of meningococcemia, the vaccine efficacy of MCV-ACWY and the price of MCV-ACWY would influence the cost-effectiveness of the meningococcal vaccination strategies. At the threshold, the probability of cost-effectiveness was 14.76% for the current strategy and 55.98% for the alternative strategy, respectively. The current meningococcal vaccination strategy had effectively prevented meningococcal disease at a low cost, but with limited serogroup coverage. Strategy using MCV-ACWY and MPV-ACWY could increase health benefits at a substantial cost at a cost-effective manner.
Collapse
Affiliation(s)
- Jianyong Shen
- Institute of Immunization and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
- Institute of Immunization and Prevention, Huzhou Municipal Center for Disease Control and Prevention, Huzhou, China
| | - Chai Ji
- Department of Children Healthcare, Children's Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, China
| | - Xiaofu Luo
- Institute of Immunization and Prevention, Huzhou Municipal Center for Disease Control and Prevention, Huzhou, China
| | - Yu Hu
- Institute of Immunization and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| |
Collapse
|
3
|
Sun M, Yan S, Cao T, Zhang J. The impact of COVID-19 pandemic on the world's major economies: based on a multi-country and multi-sector CGE model. Front Public Health 2024; 12:1338677. [PMID: 38566793 PMCID: PMC10986737 DOI: 10.3389/fpubh.2024.1338677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 02/29/2024] [Indexed: 04/04/2024] Open
Abstract
Objective To quantitatively assess the impact of COVID-19 pandemic on public health, as well as its economic and social consequences in major economies, which is an international public health concern. The objective is to provide a scientific basis for policy interventions. Subject and methods This study utilizes a multi-country, multi-sector CGE-COVID-19 model to analyze the repercussions of the pandemic in 2022. The re-search focuses on quantifying the effects of COVID-19 on the macroeconomy and various industry sectors within six economies: the United States, China, the EU, the United Kingdom, Japan, and South Korea. Results The COVID-19 pandemic shock had the most significant impact on China and the EU, followed by notable effects observed in the United States and the United Kingdom. In contrast, South Korea and Japan experienced relatively minimal effects. The reduction in output caused by the pandemic has affected major economies in multiple sectors, including real industries such as forestry and fisheries, and the services such as hotels and restaurants. Conclusion The overall negative macroeconomic impact of the epidemic on major economies has been significant. Strategic interventions encompassing initiatives like augmenting capital supply, diminishing corporate taxes and fees, offering individual subsidies, and nurturing international cooperation held the potential to mitigate the detrimental economic consequences and enhance the global-economic amid the pan-demic. Consequently, this study contributes to the advancement of global anti-epidemic policies targeting economic recovery. Moreover, using the CGE-COVID-19 model has enriched the exploration of general equilibrium models in PHEIC events.
Collapse
Affiliation(s)
- Mingsong Sun
- School of Economics and Finance, Huaqiao University, Quanzhou, China
| | - Shiling Yan
- Department of Agriculture and Forestry Technology, Weifang Engineering Vocational College, Qingzhou, China
| | - Tingting Cao
- Department of Economics and Management, Weifang University of Science and Technology, Shouguang, China
- Postdoctoral Station, Dongbei University of Finance & Economics, Dalian, China
| | - Jingwen Zhang
- Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
4
|
Vetter V, Baxter R, Denizer G, Sáfadi MAP, Silfverdal SA, Vyse A, Borrow R. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines 2016; 15:641-58. [PMID: 26651380 PMCID: PMC4841019 DOI: 10.1586/14760584.2016.1130628] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Adolescents have the highest rates of meningococcal carriage and transmission. Interrupting the adolescent habitat in order to reduce carriage and transmission within adolescents and to other age groups could help to control meningococcal disease at a population level. Compared to immunization strategies restricted to young children, a strategy focused on adolescents may have more profound and long-lasting indirect impacts, and may be more cost effective. Despite challenges in reaching this age-group, experience with other vaccines show that high vaccine coverage of adolescents is attainable.
Collapse
Affiliation(s)
| | - Roger Baxter
- b Kaiser Permanente Vaccine Study Center , Oakland , CA , U.S.A
| | | | - Marco A P Sáfadi
- c Department of Pediatrics , FCM da Santa Casa de Sáo Paulo , Sáo Paulo , Brazil
| | | | - Andrew Vyse
- a GlaxoSmithKline (GSK) Vaccines , Wavre , Belgium
| | - Ray Borrow
- e Vaccine Evaluation Unit , Public Health England , Manchester , U.K
| |
Collapse
|
5
|
Lee SO. Commencement of the meningococcal vaccination for the republic of Korea army. Infect Chemother 2013; 45:113-5. [PMID: 24265960 PMCID: PMC3780934 DOI: 10.3947/ic.2013.45.1.113] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Affiliation(s)
- Sang-Oh Lee
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
6
|
|
7
|
Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. PHARMACOECONOMICS 2010; 28:449-61. [PMID: 20465314 DOI: 10.2165/11535280-000000000-00000] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The evolution of meningococcal vaccines illustrates nicely the incremental technological process that is common to much medical innovation and particularly appropriate to economic analysis. However, the economic evaluation of vaccines is complicated by several features unique to vaccines, including the possibility of indirect (herd immunity) benefits and the shear breadth of vaccination strategies available to decision makers. As with the vaccines themselves, the modelling approaches applied to the economic evaluation of meningococcal vaccines have evolved to become increasingly complex. Despite such innovation, concerns remain about the quality of economic studies of meningococcal vaccines. This article reviews evaluations of meningococcal vaccine strategies in developed countries and provides recommendations for future work in this area. Four potentially problematic areas in the existing literature are identified - indirect costs, herd immunity, quality of life and comparison programmes - and approaches to these issues are discussed. Recommendations for reporting a 'minimum analysis profile' case are also made. Although comparisons across studies are difficult at best, recent work shows that incorporating the indirect benefits and costs of vaccination substantially improves cost effectiveness.
Collapse
Affiliation(s)
- Teresa L Kauf
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
| |
Collapse
|
8
|
Tavana AM, Ataee R. Meningococcal Meningitis Control in Iran: Five Year Comparative Study 2000-2004. JOURNAL OF MEDICAL SCIENCES 2008. [DOI: 10.3923/jms.2009.51.54] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
9
|
Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review. Epidemiol Infect 2008; 136:1441-7. [PMID: 18559124 DOI: 10.1017/s0950268808000770] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
SUMMARYWe performed a systematic review to estimate the effectiveness of vaccination, in addition to chemoprophylaxis, in preventing meningococcal disease among household contacts. Medline, EMBASE, EMGM, and EUIBIS were used for data collection. Studies reporting on at least 100 primary cases and on subsequent cases in household settings with follow-up of more than 2 weeks after onset of disease in the primary case were reviewed. A meta-analysis was used to calculate the average attack rate in household contacts given chemoprophylaxis 14-365 days after onset of disease in the primary case. In total, 652 studies were identified, five studies and one unpublished report met the inclusion criteria. The weighted average attack rate was 1.1/1000 household contacts (95% CI 0.7-1.7). This review supports vaccination of household contacts in addition to chemoprophylaxis to reduce the risk of meningococcal disease among household contacts of a case caused by a vaccine-preventable serogroup.
Collapse
|
10
|
|
11
|
Caro JJ, Möller J, Getsios D, Coudeville L, El-Hadi W, Chevat C, Nguyen VH, Caro I. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health 2007; 7:130. [PMID: 17603880 PMCID: PMC1925079 DOI: 10.1186/1471-2458-7-130] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2006] [Accepted: 06/29/2007] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Meningococcal disease can have devastating consequences. As new vaccines emerge, it is necessary to assess their impact on public health. In the absence of long-term real world data, modeling the effects of different vaccination strategies is required. Discrete event simulation provides a flexible platform with which to conduct such evaluations. METHODS A discrete event simulation of the epidemiology of invasive meningococcal disease was developed to quantify the potential impact of implementing routine vaccination of adolescents in the United States with a quadrivalent conjugate vaccine protecting against serogroups A, C, Y, and W-135. The impact of vaccination is assessed including both the direct effects on individuals vaccinated and the indirect effects resulting from herd immunity. The simulation integrates a variety of epidemiologic and demographic data, with core information on the incidence of invasive meningococcal disease and outbreak frequency derived from data available through the Centers for Disease Control and Prevention. Simulation of the potential indirect benefits of vaccination resulting from herd immunity draw on data from the United Kingdom, where routine vaccination with a conjugate vaccine has been in place for a number of years. Cases of disease are modeled along with their health consequences, as are the occurrence of disease outbreaks. RESULTS When run without a strategy of routine immunization, the simulation accurately predicts the age-specific incidence of invasive meningococcal disease and the site-specific frequency of outbreaks in the Unite States. 2,807 cases are predicted annually, resulting in over 14,000 potential life years lost due to invasive disease. In base case analyses of routine vaccination, life years lost due to infection are reduced by over 45% (to 7,600) when routinely vaccinating adolescents 12 years of age at 70% coverage. Sensitivity analyses indicate that herd immunity plays an important role when this population is targeted for vaccination. While 1,100 cases are avoided annually when herd immunity effects are included, in the absence of any herd immunity, the number of cases avoided with routine vaccination falls to 380 annually. The duration of vaccine protection also strongly influences results. CONCLUSION In the absence of appropriate real world data on outcomes associated with large-scale vaccination programs, decisions on optimal immunization strategies can be aided by discrete events simulations such as the one described here. Given the importance of herd immunity on outcomes associated with routine vaccination, published estimates of the economic efficiency of routine vaccination with a quadrivalent conjugate vaccine in the United States may have considerably underestimated the benefits associated with a policy of routine immunization of adolescents.
Collapse
Affiliation(s)
- J Jaime Caro
- Caro Research Institute, 336 Baker, Concord, MA, USA
- Division of General Internal Medicine and Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Jörgen Möller
- Caro Research Institute, Vaggarpsvagen 11, SE24193 Eslov, Sweden
| | - Denis Getsios
- Caro Research Institute, 6415 Seaforth Street, Halifax, NS B3L 1R4, Canada
| | - L Coudeville
- sanofi pasteur, 2 Ave du Pont Pasteur, 69367 Lyon cedex 07, Lyon, France
| | | | - Catherine Chevat
- sanofi pasteur, 2 Ave du Pont Pasteur, 69367 Lyon cedex 07, Lyon, France
| | - Van Hung Nguyen
- sanofi pasteur, 2 Ave du Pont Pasteur, 69367 Lyon cedex 07, Lyon, France
| | - Ingrid Caro
- Caro Research Institute, 185 Dorval Ave., Montreal, Quebec, H9S 5J9, Canada
| |
Collapse
|
12
|
Bishai D, Brice R, Girod I, Saleh A, Ehreth J. Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. PHARMACOECONOMICS 2007; 25:143-54. [PMID: 17249856 DOI: 10.2165/00019053-200725020-00006] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
OBJECTIVE To estimate the willingness of parents in France and Germany to pay for meningococcal conjugate vaccines for their teenage children. METHODS A conjoint analysis survey was administered to parents who had received counselling on the nature and risks of meningococcal disease in young people. In each country, half were randomly assigned to view a video with graphical depictions of the effects of meningococcaemia. Subjects were then shown a series of 18 sets of three vaccine descriptions. Each description listed the price of a hypothetical vaccine (range 15-304 euro; 2001 values), the duration of protection, and the number of serogroups of the bacteria covered. The survey asked which vaccine they preferred and whether they would buy it. Conditional logit and generalised linear-random effects logit models assessed the effect of product attributes, personal background and video viewership on the probability of indicating a purchase. RESULTS 92.6% of subjects would purchase at least one of the vaccines they encountered. Price elasticity ranged from -1.20 (France) to -2.48 (Germany). Exposure to graphical depictions of disease consequences negligibly increased the overall willingness to purchase vaccine in French participants, but lowered the overall willingness in German participants. CONCLUSION In Germany and France, where there is still limited out-of-pocket health spending, the majority of sampled respondents stated that they would purchase meningococcal vaccines with their own money.
Collapse
Affiliation(s)
- David Bishai
- Department of Population and Family Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21030, USA.
| | | | | | | | | |
Collapse
|
13
|
Butler KM. Meningococcal Meningitis Prevention Programs for College Students: A Review of the Literature. Worldviews Evid Based Nurs 2006; 3:185-93. [PMID: 17177931 DOI: 10.1111/j.1741-6787.2006.00069.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE The incidence of meningococcal meningitis in college students is higher than in other populations. College students, especially 1st-year students living in dormitories or residence halls, are among those at highest risk of developing the disease. It is estimated that immunization can prevent up to 83% of cases among adolescents and college students. A review of the literature was undertaken to identify and critique the research-based prevention programs that are focused on college students. METHOD An extensive search of the Cochrane Database of systematic reviews, Medline, PubMed, and CINAHL was undertaken. The Journal of American College Health was hand searched, and bibliographies were reviewed for studies not otherwise identified. Four publications met the search criteria. These studies were reviewed and graded for level of evidence. FINDINGS One study could not be compared with the other three because of its lack of detail. Of the other three studies, two were descriptive and factors were identified that related to vaccination and nonvaccination in the college student population (both Evidence Grade C). Only one study was described that included an educational intervention, which resulted in increased vaccination rates in a college student population (Evidence Grade B). CONCLUSIONS AND IMPLICATIONS The published literature is severely limited in the area of meningococcal meningitis prevention programs in the at-risk college student population. A critical need exists for controlled studies to test the interventions that are most effective in this population as well as broader-based studies to further identify those students at increased risk for the disease as well as for nonvaccination.
Collapse
Affiliation(s)
- Karen M Butler
- College of Nursing, University of Kentucky, Lexington, KY 40536, USA.
| |
Collapse
|
14
|
Abstract
Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.
Collapse
Affiliation(s)
- Lee H Harrison
- Infectious Diseases Epidemiology Research Unit, 521 Parran Hall, 130 Desoto St., University of Pittsburgh, Pittsburgh, PA 15261, USA.
| |
Collapse
|
15
|
Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. PHARMACOECONOMICS 2005; 23:855-74. [PMID: 16153131 DOI: 10.2165/00019053-200523090-00001] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
In recent years, several countries have experienced increases in the incidence of serogroup C meningococcal disease. It can be controlled with older polysaccharide vaccines and particularly the recently developed conjugate vaccines. For 21 developed countries, we investigated the role that economic evaluation played in the decision to introduce the conjugate vaccine into either the routine childhood vaccination schedule, as a mass vaccination 'catch-up' campaign or not at all. A literature review was performed and experts from these countries were contacted. For six countries, we identified published economic evaluations for meningococcal C conjugate vaccination. In four of them (Australia, Canada [Quebec], The Netherlands and the UK) the analyses were performed before a decision about the use of the conjugate vaccine was made. In all of these countries, the economic evaluation offered guidance as to the most efficient way to add the conjugate vaccine to the routine infant immunisation schedule and, in three countries, this advice was adopted by decision makers. In Portugal and Switzerland, initial vaccination decisions were made without the economic evaluations that are influencing current decision making. Of the countries without economic evaluations, six implemented vaccination programmes. Overall, there was a positive correlation between the reported incidence of meningococcal C disease and (a) the decision to vaccinate and (b) performing an economic evaluation. All economic evaluations were modelling studies. The reported cost-effectiveness ratios were sensitive to the age of vaccination, the future meningococcal incidence, vaccine price and some methodological characteristics that varied widely between studies making direct comparisons difficult. In conclusion, in almost all countries where economic evaluations for meningococcal C conjugate vaccinations have been conducted, their results had an important role in the decision-making process. However, in most countries with strongly increasing meningococcal incidence, public health considerations took precedence. In order to improve the international comparability of such studies, firmer national and international modelling guidelines and better adherence to such guidelines seem necessary.
Collapse
Affiliation(s)
- Robert Welte
- Institute of Health Economics and Health Care Management, GSF-National Research Center for Environment and Health, Neuherberg, Germany.
| | | | | | | | | |
Collapse
|
16
|
Miller MA, Shahab CK. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. PHARMACOECONOMICS 2005; 23:333-43. [PMID: 15853434 DOI: 10.2165/00019053-200523040-00004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Outbreaks of meningococcal disease have caused devastation worldwide. Effective vaccines have not been used routinely, due to perceived limitations of the duration of effectiveness as well as immunogenicity when administered during infancy. Given the sporadic nature of outbreaks, the optimal use of these vaccines to control both short-term epidemic and endemic meningococcal disease has been the subject of much debate. Seven economic studies on the use of polysaccharide vaccination strategies help to highlight the relevant epidemiological and economic issues surrounding the decisions for their use. Five of these studies were based in Africa, the region where annual incidence rates can be several orders of magnitude greater than the rest of the world. These studies demonstrated that vaccination against meningococcal disease during outbreak situations is suboptimal given the inability to rapidly immunise populations in a timely fashion in resource-poor areas. However, depending on the disease incidence and the ability to deliver vaccines, the polysaccharide vaccine can be cost effective for preventive strategies when given prior to the start of outbreaks, either through presumptive vaccination or through a modified routine delivery strategy. Economic analyses of mass immunisation campaigns and modelled routine vaccination suggest that routine use of meningococcal vaccines for preventive strategies could be within the range of cost-effective public health interventions in those regions of the world where meningococcal disease is endemic. This includes the meningococcal belt of Africa, the Sahelian region.
Collapse
Affiliation(s)
- Mark A Miller
- Division on International Epidemiology and Population Studies, Fogarty Internatonal Center, National Institutes of Health, Building 16, 16 Center Drive, Bethesda, MD 20892-6705, USA.
| | | |
Collapse
|
17
|
Getsios D, Caro I, El-Hadi W, Caro JJ. Assessing the economics of vaccination forNeisseria meningitidisin industrialized nations: A review and recommendations for further research. Int J Technol Assess Health Care 2004; 20:280-8. [PMID: 15446757 DOI: 10.1017/s0266462304001096] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Objectives:To review the existing health economic literature on meningococcal disease vaccination.Methods:A Medline search for economic evaluations of vaccination programs for meningococcal disease in developed countries was conducted. All identified studies were reviewed.Results:Nine published studies were identified examining either mass vaccination during outbreaks or routine vaccination. Although net expenses were estimated in almost all studies, the resulting cost-effectiveness ratios varied widely. Vaccination of college-age students was found to be potentially cost-effective in Australia but not in the United States. With one exception, routine vaccination of children and adolescents in Europe was predicted to be cost-effective. Many simplifying assumptions were made, and important elements were often left out, in particular the potential for reduced transmission of disease.Conclusions:The methods used and the vaccination strategies vary widely, and results do not provide strong grounds for making conclusions as to whether vaccination is cost-effective. Furthermore, in all instances, transmission of disease, changes in population carriage rates, and outbreaks are either ignored, dealt with using very broad simplifying assumptions, or are not necessarily generalizable to other settings. The analyses provide some insight into the potential cost-effectiveness of vaccination, but more importantly, they highlight areas requiring further study. Economic evaluations based on observed outcomes from recently implemented strategies would be helpful, as would more sophisticated health economic models. The choice of vaccination strategies cannot be based on the results of existing economic analyses.
Collapse
|
18
|
De Wals P. Should university students be vaccinated against meningococcal disease in Canada? Can J Infect Dis 2004; 15:25-8. [PMID: 18159440 PMCID: PMC2094918 DOI: 10.1155/2004/740537] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2003] [Accepted: 11/28/2003] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE To evaluate the benefit and costs of vaccination of university students against invasive meningococcal disease (IMD) in Canada. METHODS Published studies were reviewed and a simulation model was used. RESULTS IMD risk seems to be of low magnitude, but consequences can be dramatic. Over a 10-year period, IMD risk reduction would be slightly greater using a monovalent C conjugate vaccine than a quadrivalent polysaccharide vaccine. From a societal perspective, costs per quality-adjusted life-years gained would be between $135,000 and $698,000, according to epidemiological scenarios and with vaccine purchase prices between $35 and $50 per dose. CONCLUSIONS Economic indices exceed proposed criteria for cost effective public health programs, but from the perspective of students and parents, the cost of vaccination might be worth the benefit.
Collapse
Affiliation(s)
- Philippe De Wals
- Department of Social and Preventive Medicine, Laval University and National Institute of Public Health, Quebec City, Quebec
| |
Collapse
|
19
|
Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. JOURNAL OF AMERICAN COLLEGE HEALTH : J OF ACH 2003; 51:227-236. [PMID: 14510025 DOI: 10.1080/07448480309596355] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Hepatitis B immunization is recommended for all American children, and hepatitis A immunization is recommended for children who live in areas with elevated disease rates. Because hepatitis A and B occur most commonly in young adults, the authors examined the cost effectiveness of college-based vaccination. They developed epidemiologic models to consider infection risks and disease progression and then compared the cost of vaccination with economic, longevity, and quality of life benefits. Immunization of 100,000 students would prevent 1,403 acute cases of hepatitis A, 929 cases of hepatitis B, and 144 cases of chronic hepatitis B. Hepatitis B vaccination would cost the health system $7,600 per quality-adjusted life year (QALY) gained but would reduce societal costs by 6%. Hepatitis A/B vaccination would cost the health system dollar 8,500 per QALY but would reduce societal costs by 12%. Until childhood and adolescent vaccination can produce immune cohorts of young adults, college-based hepatitis immunization can reduce disease transmission in a cost-effective manner.
Collapse
Affiliation(s)
- R Jake Jacobs
- Capitol Outcomes Research, Alexandria, Virginia 22310, USA.
| | | | | |
Collapse
|
20
|
Brundage JF, Ryan MAK, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis 2002; 35:1376-81. [PMID: 12439801 DOI: 10.1086/344273] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2001] [Accepted: 08/09/2002] [Indexed: 11/03/2022] Open
Abstract
Historically, military recruits have been at high risk of acquiring meningococcal disease. Beginning in the 1940s, the US military relied on mass treatment with sulfadiazine to control outbreaks in training camps. In the 1960s, a vaccine was developed in response to the emergence of sulfadiazine-resistant strains. Since 1971, all new recruits in the US military have been immunized against Neisseria meningitidis during their first days of service. Serogroups represented in vaccines given to service members have changed over time: the quadrivalent (A, C, Y, W135) vaccine has been given since 1982. In the US military, meningococcal disease rates decreased by approximately 94% from 1964 to 1998. After initiating routine immunization in 1971, crude rates decreased sharply and have remained low; in addition, there have been few cases of disease caused by serogroups represented in contemporaneously administered vaccines. In the US military, immunizations have been effective for the prevention of disease caused by vaccine-homologous serogroups of N. meningitidis.
Collapse
Affiliation(s)
- John F Brundage
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, USA
| | | | | | | |
Collapse
|
21
|
Abstract
OBJECTIVE To discuss the role of meningococcal vaccine in prevention of meningococcal disease. DATA SOURCES A MEDLINE search (1966-June 2001) was performed to identify key literature. Search terms included, but were not limited to, meningococcal vaccines, meningococcal meningitis, meningococcal infection, and meningococcus. The search was limited to English-language literature and references dealing with humans. The MEDLINE search was supplemented by a hand search of various bibliographies. DATA SYNTHESIS The impact of meningococcal disease has caused national and regional organizations to develop recommendations for use of meningococcal vaccine. Even though the meningococcal vaccine can provide benefit, limitations exist. The available vaccine does not cover all meningococcal strains and is not useful in all age groups. The appropriate target groups for prevention of disease through vaccination have been difficult to determine; vaccine use in college students is especially controversial. CONCLUSIONS Although a meningococcal vaccine is available, meningococcus causes significant morbidity and mortality. Controversy exists over the meningococcal vaccine and its use. Students entering college who will be living in dormitories should be informed of the increased risk of meningococcal disease and be offered vaccination.
Collapse
|
22
|
Scott RD, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis. Am J Prev Med 2002; 23:98-105. [PMID: 12121797 DOI: 10.1016/s0749-3797(02)00462-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND Surveillance of meningococcal disease among U.S. college students found an elevated rate of this disease among first-year students living in dormitories. OBJECTIVE This study examines the economics of routinely vaccinating a cohort of 591,587 incoming first-year students who will live in dormitories for > or =1 years. METHODS A cost-benefit model (societal perspective) was constructed to measure the net present value (NPV) of various vaccination scenarios, as well as the cost/case and cost/death averted. Input values included hospitalization costs from $10,924 to $24,030 per hospitalization; immunization costs (vaccine plus administration costs) from $54 to $88 per vaccine; 30 nonfatal, vaccine-preventable cases over a 4-year period (includes 3 with sequelae); 3 premature deaths; value of human life from $1.2 million to $4.8 million; and long-run sequelae costs from $1298 to $14,600. Sensitivity analyses were also conducted on vaccine efficacy (80% to 90%); discount rate (0% to 5%); and coverage (60% to 100%). RESULTS The costs of vaccination outweighed the benefits gained with NPVs ranging from -$11 million to -$49 million. The net cost per case averted ranged from $0.6 million to $1.9 million. The net cost per death averted ranged from $7 million to $20 million. The break-even costs of vaccination (when NPV=$0) at 60% coverage ranged from $23 (90% vaccine efficacy) to $5 (80% efficacy). CONCLUSIONS The model showed that the vaccination program is not cost-saving. Key variables influencing the results were the low number of vaccine-preventable cases and the high cost of vaccination. However, from the perspective of students and parents, the cost of vaccination might be worth the real or perceived benefit of reducing the risk to an individual student of developing meningococcal disease.
Collapse
Affiliation(s)
- R Douglas Scott
- Division of Healthcare Quality Promotion (Scott), National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
| | | | | | | | | |
Collapse
|
23
|
Grabenstein JD. Meningococcal Vaccines: Expanding Protection from Infants to College. Hosp Pharm 2001. [DOI: 10.1177/001857870103601011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunopro-phylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.
Collapse
|
24
|
Dennehy PH. Active immunization in the United States: developments over the past decade. Clin Microbiol Rev 2001; 14:872-908, table of contents. [PMID: 11585789 PMCID: PMC89007 DOI: 10.1128/cmr.14.4.872-908.2001] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The Centers for Disease Control and Prevention has identified immunization as the most important public health advance of the 20th century. The purpose of this article is to review the changes that have taken place in active immunization in the United States over the past decade. Since 1990, new vaccines have become available to prevent five infectious diseases: varicella, rotavirus, hepatitis A, Lyme disease, and Japanese encephalitis virus infection. Improved vaccines have been developed to prevent Haemophilus influenzae type b, pneumococcus, pertussis, rabies, and typhoid infections. Immunization strategies for the prevention of hepatitis B, measles, meningococcal infections, and poliomyelitis have changed as a result of the changing epidemiology of these diseases. Combination vaccines are being developed to facilitate the delivery of multiple antigens, and improved vaccines are under development for cholera, influenza, and meningococcal disease. Major advances in molecular biology have enabled scientists to devise new approaches to the development of vaccines against diseases ranging from respiratory viral to enteric bacterial infections that continue to plague the world's population.
Collapse
Affiliation(s)
- P H Dennehy
- Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island 02903, USA.
| |
Collapse
|
25
|
Jacobs RJ, Koff RS. Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000; 32:873-4; author reply 874-5. [PMID: 11041688 DOI: 10.1053/jhep.2000.18856] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
|
26
|
Harrison LH. Preventing meningococcal infection in college students. Clin Infect Dis 2000; 30:648-51. [PMID: 10770724 DOI: 10.1086/313741] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2000] [Indexed: 11/03/2022] Open
Abstract
The incidence of invasive meningococcal disease in adolescents and young adults of high school and college age has recently increased in the United States. Recent studies indicate that certain groups of college students are at increased risk. This has led to the recent Advisory Committee Immunization Practices recommendation that college freshman dormitory residents be provided information about meningococcal infection and the benefits of vaccination. Future studies will need to focus on the potential vaccine prevention of the increased risk of meningococcal infection in persons of high school age, particularly as new conjugate meningococcal vaccines become available.
Collapse
Affiliation(s)
- L H Harrison
- Infectious Diseases Epidemiology Research Unit, Departments of Medicine and Epidemiology, University of Pittsburgh School of Medicine PA 15261, USA.
| |
Collapse
|
27
|
Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RC, Madeley RJ, Ait-Tahar K, Job K, Wale MC, Ala'Aldeen DA. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ (CLINICAL RESEARCH ED.) 2000; 320:846-9. [PMID: 10731181 PMCID: PMC27326 DOI: 10.1136/bmj.320.7238.846] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 01/02/2000] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To determine the rates of, and risk factors for, meningococcal carriage and acquisition among university students. DESIGN Repeated cross sectional study. PARTICIPANTS 2,507 students in their first year at university. MAIN OUTCOME MEASURES Prevalence of carriage of meningococci and risk factors for carriage and acquisition of meningococci. RESULTS Carriage rates for meningoccoci increased rapidly in the first week of term from 6.9% on day 1, to 11.2% on day 2, to 19.0% on day 3, and to 23.1% on day 4. The average carriage rate during the first week of term in October among students living in catered halls was 13.9%. By November this had risen to 31.0% and in December it had reached 34. 2%. Independent associations for acquisition of meningococci in the autumn term were frequency of visits to a hall bar (5-7 visits: odds ratio 2.7, 95% confidence interval 1.5 to 4.8), active smoking (1.6, 1.0 to 2.6), being male (1.6, 1.2 to 2.2), visits to night clubs (1. 3, 1.0 to 1.6), and intimate kissing (1.4, 1.0 to 1.8). Lower rates of acquisition were found in female only halls (0.5, 0.3 to 0.9). The most commonly acquired meningococcal strain was C2a P1.5 (P1.2), which has been implicated in clusters of invasive meningococcal disease at other UK universities. CONCLUSIONS Carriage rates of meningococci among university students increase rapidly in the first week of term, with further increases during the term. The rapid rate of acquisition may explain the increased risk of invasive meningococcal disease and the timing of cases and outbreaks in university students.
Collapse
Affiliation(s)
- K R Neal
- Department of Public Health Medicine and Epidemiology, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
A comprehensive review of all major agents causing bacterial meningitis--meningococcus of the groups A, B, C, W135, and Y, pneumococcus, and Haemophilus influenzae type B (Hib)--is done in terms of preventing them by chemoprophylaxis or vaccination. Some evidence suggests that the group B meningococcal disease may also be very likely preventable by a vaccine that is already available. Excellent Hib conjugates use a technique that is expected to revolutionize immunoprophylaxis against most meningococcal and pneumococcal diseases in the near future. Unfortunately, the high cost of conjugate vaccines restricts their use in many poor countries.
Collapse
Affiliation(s)
- H Peltola
- Department of Infectious Diseases, Helsinki University Central Hospital, Finland
| |
Collapse
|
29
|
McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science. PHARMACOECONOMICS 1999; 15:357-367. [PMID: 10537954 DOI: 10.2165/00019053-199915040-00003] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as treatment costs averted. Many such economic evaluations are, according to the 'scientific' definition, CBAs. The 'balance-sheet' (or opportunity cost) approach is a form of CBA which can be used to identify who bears the costs and who reaps the benefits from any change. Whilst the next stage in a CBA, as defined in health economics, would require that all costs and benefits be valued in monetary terms, the balance-sheet approach, however, advocates that available monetary values can be augmented by other measures of cost and benefit. As such, this approach, which has a theoretical basis, is proposed as a practical prescription for CBA and highlights the notion that unquantified benefits are important and can be included within CBAs even when monetarisation is not possible. Recent methodological developments in monetary valuation for use in CBA are the development of the technique of willingness to pay, the use of conjoint analysis (CA) to elicit willingness-to-pay (WTP) values and advances in the debate on the inclusion of production gains in CBAs. Whilst acknowledging that there have been developments in each of these areas, it is claimed there has also been progress in using CBA as a framework for evaluation, as reflected by the balance-sheet approach. The paper concludes by stating that almost all types of economic evaluation have an element of the 'cost-benefit' approach in them. The important issue is to focus on the policy question to be addressed and to outline the relevant costs and benefits in a manner which assists the evaluation of welfare changes resulting from changes in healthcare delivery. The focus should not be on moulding a question to fit a hybrid definition of an analytical technique.
Collapse
Affiliation(s)
- E McIntosh
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
| | | | | |
Collapse
|
30
|
Chang WY, Henry BM. Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. Nurs Res 1999; 48:94-104. [PMID: 10190836 DOI: 10.1097/00006199-199903000-00008] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Cost analyses are needed to inform resource decisions. Oftentimes, however cost-benefit analysis (CBA), cost-effectiveness analysis (CEA), cost-minimization analysis (CMA), and cost-utility analysis (CUA) are performed using untested techniques and adhering to a variety of questionable principles. OBJECTIVES To analyze, compare, and present a set of useful principles for the main types and methods of cost analyses through a synthesis of current information in the published literature. METHODS The area of interest included all reports of cost research published as full articles in professional journals from January 1990 to August 1996 in the nursing, medical, and health services fields. In all, 88 sampled articles met the criteria for inclusion. A four-page data collection guide with 28 items grouped as demographics, cost-analysis types, methods, and principles was designed for the review. Incremental testing for interrater reliability using the kappa statistic for two raters was performed. Sampling, process-oriented, construct, and correlational validity were assessed. RESULTS The 88 articles included 4 from nursing, 59 from medical, and 25 from health services journals. Of these articles, 45 (51%) reported CBA, 36 (41%) CEA, 2 CMA, 4 CUA, and 1 both CBA and CEA. Three nursing studies were authored only by nurses. Three fourths of the medical and four fifths of the health services publications had interdisciplinary authorship. Existing databases were the primary source of data in 61 (69%) publications. Adherence to six main methodologic principles was apparent in 19 (22%) articles. None of the nursing studies adhered to all six principles, whereas 16% of the health services and 25% of the medical studies did. CONCLUSIONS Funded cost analyses of nursing interventions that adhere to the six known methodologic principles are needed to inform policy-level health care decisions. Because of the complexity of cost analysis methodology, including sensitivity analysis, future interdisciplinary efforts using existing databases may prove most effective. The six methodologic principles presented in this article can be useful for future nursing education and cost-analysis research designed to control cost and increase the quality of health care.
Collapse
Affiliation(s)
- W Y Chang
- University of Illinois at Chicago, College of Nursing, 60612-7350, USA
| | | |
Collapse
|
31
|
Abstract
Meningococcal disease causes great emotion and anxiety in the families and caregivers of patients. Numbers of such patients are usually small in industrialised countries, unlike those in many regions--especially in subsahelian Africa. Vaccines have been tried for more than 80 years; at present there are available polysaccharide vaccines against groups A, C, Y and W135, and a protein-based vaccine against group B. A property common to all is their relative efficacy (75 to 100%) at school age and after, and an acceptably short persistence of antibodies. Small children pose the major challenge, in whom there is essentially evidence of clinical protection only against group A and C diseases. With vaccines against other serogroups protection is possible, but not yet proven in controlled clinical studies. The search is on for help from various modifications, including the conjugation technique, to transform the independent nature of polysaccharide response towards T cell dependence, as was done earlier in Haemophilus influenzae type b vaccines. First trials along this path are encouraging although, again, group B meningococci pose special problems. The next few years will probably see a new generation of meningococcal vaccines. Generally speaking, the incidence of meningococcal disease is too low to indicate vaccinations for the whole population, or even children, but some risk groups and epidemics are important exceptions. To date, bivalent group A + C or tetravalent group A + C + Y + W135 polysaccharides, or an outer membrane protein-based group B vaccine, are the products to be used when the indications, that may vary from country to country, are considered met. A strong herd immunity effect, demonstrated with group A and C vaccinations, facilitates extinction of an epidemic since large-scale vaccinations can be restricted only in the major risk groups, children and in various schools. Prompt intervention demands, however, a functioning mechanism which detects very early on a pending epidemic. Unfortunately, such a mechanism is often lacking in countries often hit by this deadly disease.
Collapse
Affiliation(s)
- H Peltola
- Division of Infectious Diseases, Helsinki University Central Hospital, Hospital for Children and Adolescents, Finland
| |
Collapse
|
32
|
Abstract
Meningococcal disease continues to be a great health problem on all continents and the meningococcal vaccines have been proposed for their prevention and epidemic control. The polysaccharide A and C vaccines are relatively efficacious with distinct immunological behavior with regard to the different age groups, however, up to the present no highly efficacious vaccine for meningococcal B disease exists. The meningococcal B capsular polysaccharide is not immunogenic due to the structural mimicry of mammalian tissues and efforts to produce carrier proteins have been proposed in order to obtain an immunogenic vaccine for all age groups that would if possible, protect against all the meningococci. This review of the literature presents the study of the development of the immunological behavior of all the meningococcal vaccines undergoing development and reports on the efforts to obtain a safe and efficacious product for the control of meningococcal disease.
Collapse
Affiliation(s)
- H I Requejo
- Seção de Imunologia do Instituto Adolfo Lutz, São Paulo, Brasil
| |
Collapse
|
33
|
Zarnke KB, Levine MA, O'Brien BJ. Cost-benefit analyses in the health-care literature: don't judge a study by its label. J Clin Epidemiol 1997; 50:813-22. [PMID: 9253393 DOI: 10.1016/s0895-4356(97)00064-4] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVES To assess whether health-care related economic evaluations labeled as "cost benefit analyses" (CBA) meet a contemporary definition of CBA methodology and to assess the prevalence of methods used for assigning monetary units to health outcomes. DATA SOURCES Medline, Current Contents, and HSTAR databases and reference lists of review articles, 1991-1995. STUDY SELECTION Economic analyses labeled as CBAs were included. Agreement on study selection was assessed. STUDY EVALUATION: CBA studies were classified according to standard definitions of economic analytical techniques. For those valuing health outcomes in monetary units (bona fide CBAs), the method of valuation was classified. RESULTS 53% of 95 studies were reclassified as cost comparisons because health outcomes were not appraised. Among the 32% considered bona fide CBAs, the human capital approach was employed to value health states in monetary units in 70%. Contingent valuation methods were employed infrequently (13%). CONCLUSIONS Studies labeled as CBAs in the health-care literature often offer only partial program evaluation. Decisions based only on resource costs are unlikely to improve efficiency in resource allocation. Among bona fide CBAs, the human capital approach was most commonly used to valuing health, despite its limitations. The results of health-care related CBAs should be interpreted with extreme caution.
Collapse
Affiliation(s)
- K B Zarnke
- Department of Medicine, London Health Sciences Centre, University of Western Ontario, Ontario, Canada
| | | | | |
Collapse
|
34
|
|